tirzepatide surpass trials Efficacy and safety of monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial SURPASS to SURMOUNT: The Tirzepatide

[1] Incretins such as GLP-1 inhibit glucagon release from the alpha cells of the islets of Langerhans

Key Technical Properties Distinct deep cobalt blue color (indicates intact Cu coordination) High stability constant (log K 16.4) SIRT1 protein binding modulator Storage & Handling Lab Name Verified Research Lab Store at -20C or 28C

TEAE = treatment-emergent adverse event

GLP-1 medications (Glucagon-Like Peptide-1 agonists) mimic a natural hormone that helps regulate appetite and blood sugar

However, you should ensure thyroid hormone levels are optimized before starting treatment, and thyroid function should be rechecked 68 weeks after beginning semaglutide